Novartis has settled a lawsuit brought by the estate of Henrietta Lacks, which claimed that the pharmaceutical company unjustly profited from her cells taken without consent in 1951. These cells, known as HeLa cells, have been instrumental in numerous medical breakthroughs, including the development of the polio vaccine and advancements in cancer research.
The settlement, concluded in federal court in Maryland this month, remains undisclosed, leaving key details about the agreement and its implications for the industry unclear. This case underscores the ongoing ethical debates surrounding consent and the commercialization of biological materials, raising questions about how the pharmaceutical industry navigates these complex issues. As companies continue to leverage human biological samples for research and development, the Lacks case serves as a poignant reminder of the need for transparency and ethical considerations in sourcing practices.
Use the database as your supply chain compass →
